We provide a state-of-the-art functional genomics platform to characterize both drug targets and the mode-of-action of bioactive molecules for oncology, cardiovascular and gynecological research.
Our indication specialists develop cellular assays for projects in oncology, cardiovascular and gynecological research. This includes modulation of your genes of interest by RNA interference and CRISPR/Cas9 in a broad range of cell types. In addition to targeting single genes, we perform CRISPR/Cas9-based genome-wide cellular screens for target identification/validation and compound target deconvolution with tailored indication-specific read-outs.
Our versatile next generation sequencing platform supports mode-of-action analyses, biomarker identification projects, and model characterisation approaches.
We provide analysis of DNA (exome, whole genome), RNA, Chromatin-IP, methylation (bisulfite) and quantification of e.g. CRISPR barcodes. This is complemented by 10x Genomics-based single cell sequencing to explore cellular heterogeneity and to identify novel targets and biomarker candidates.